Myeloid Therapeutics
Signal active
Organization
Contact Information
Overview
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
About
Industries
Biotechnology, Life Science, Therapeutics
Founded
2019
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Myeloid Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $6.8B in funding across 36 round(s). With a team of 11-50 employees, Myeloid Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Myeloid Therapeutics, raised $73.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
6
Lead Investors
0
Total Funding Amount
$189.3M
Details
2
Myeloid Therapeutics has raised a total of $189.3M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 50.0M | ||
| 2023 | Early Stage Venture | 73.0M |
Investors
Myeloid Therapeutics is funded by 18 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Alexandria Venture Investments | - | FUNDING ROUND - Alexandria Venture Investments | 73.0M |
| ARCH Venture Partners | - | FUNDING ROUND - ARCH Venture Partners | 73.0M |
| Myeloid Therapeutics | - | FUNDING ROUND - Myeloid Therapeutics | 73.0M |
| 8VC | - | FUNDING ROUND - 8VC | 73.0M |
Recent Activity
There is no recent news or activity for this profile.